Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines

International Journal of Oncology

Volumn 40, Issue 4, 2012, Pages 1005-1010

  Uchibori, Kazuya ^a   Kasamatsu, Atsushi ^a,b   Sunaga, Masahiko ^c   Yokota, Satoshi ^a   Sakurada, Tomoya ^a   Kobayashi, Eriko ^a   Yoshikawa, Masaharu ^a   Uzawa, Katsuhiro ^a,b   Ueda, Shiro ^a   Tanzawa, Hideki ^a,b   Sato, Nobunori ^a  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

^c Chiba Central Medical Center   (Japan)

Author keywords

5 fluorouracil; Drug resistance; Epithelial to mesenchymal transition; Hepatocellular carcinoma

Indexed keywords

FLUOROURACIL; MULTIDRUG RESISTANCE PROTEIN 5; RIBONUCLEOTIDE REDUCTASE; TRANSCRIPTION FACTOR TWIST; UVOMORULIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CELL ADHESION; CELL COUNT; CELL GROWTH; CELL STRUCTURE; DOWN REGULATION; DRUG METABOLISM; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NICK END LABELING; PHENOTYPE; PRIORITY JOURNAL; PSEUDOPODIUM; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPINDLE CELL; UPREGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FLUOROURACIL; HUMANS; IN SITU NICK-END LABELING; LIVER NEOPLASMS;

EID: 84858690933     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1300     Document Type: Article

References (35)

1. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006. (Pubitemid 46655601)
2. Wang XN, Han X, Xu LN, Yin LH, Xu YW, Qi Y and Peng JY: Enhancement of apoptosis of human hepatocellular carcinoma SMMC-7721 cells through synergy of berberine and evodiamine. Phytomedicine 15: 1062-1068, 2008.
3. Ming ZJ, Hu Y, Qiu YH, Cao L and Zhang XG: Synergistic effects of beta-aescin and 5-fluorouracil in human hepatocellular carcinoma SMMC-7721 cells. Phytomedicine 17: 575-580, 2010.
4. Higuchi E, Oridate N, Furuta Y, Suzuki S, Hatakeyama H, Sawa H, Sunayashiki-Kusuzaki K, Yamazaki K, Inuyama Y and Fukuda S: Differentially expressed genes associated with CIS-diamminedichloroplatinum (II) resistance in head and neck cancer using differential display and CDNA microarray. Head Neck 25: 187-193, 2003. (Pubitemid 36245876)
5. Scotto KW and Bertino JR: Natural and acquired resistance to chemotherapeutic agents. In: The Molecular Basis of Cancer, 2nd edition. W. B. Sanders, Foster City, pp407-422, 2001.
6. Johnston PG, Drake JC, Trepel J and Allegra CJ: Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 52: 4306-4312, 1992.
7. Aschele C, Sobrero A, Faderan MA and Bertino JR: Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 52: 1855-1864, 1992.
8. Copur S, Aiba K, Drake JC, Allegra CJ and Chu E: Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 49: 1419-1426, 1995.
9. Berger SH, Jenh CH, Johnson LF and Berger FG: Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol 28: 461-467, 1985. (Pubitemid 16224251)
10. Berger SH and Berger FG: Thymidylate synthase as a determinant of 5-fluoro-2′-deoxyuridine response in human colonic tumor cell lines. Mol Pharmacol 34: 474-479, 1988.
11. Jin S and Scotto KW: Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol 18: 4377-4384, 1998. (Pubitemid 28287960)
12. Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 12: 4147-4153, 2006.
13. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU and Gallick GE: Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 14: 3629-3637, 2007. (Pubitemid 350160137)
14. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454, 2002.
15. Thiery JP and Chopin D: Epithelial cell plasticity in development and tumor progression. Cancer Metastasis Rev 18: 31-42, 1999. (Pubitemid 29411090)
16. Elliott BE, Hung WL, Boag AH and Tuck AB: The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer. Can J Physiol Pharmacol 80: 91-102, 2002. (Pubitemid 34258657)
17. Chung YM, Park S, Park JK, Kim Y, Kang Y and Yoo YD: Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells. Cancer Lett 159: 95-101, 2000.
18. Negoro K, Yamano Y, Fushimi K, Saito K, Nakatani K, Shiiba M, Yokoe H, Bukawa H, Uzawa K, Wada T, Tanzawa H and Fujita S: Establishment and characterization of a cisplatin-resistant cell line, KB-R, derived from oral carcinoma cell line, KB. Int J Oncol 30: 1325-1332, 2007.
19. Nakamura M, Nakatani K, Uzawa K, Ono K, Uesugi H, Ogawara K, Shiiba M, Bukawa H, Yokoe H, Wada T, Fujita S and Tanzawa H: Establishment and characterization of a cisplatin-resistant oral squamous cell carcinoma cell line, H-1R. Oncol Rep 14: 1281-1286, 2005.
20. Nakatani K, Nakamura M, Uzawa K, Wada T, Seki N, Tanzawa H and Fujita S: Establishment and gene analysis of a cisplatin-resistant cell line, Sa-3R, derived from oral squamous cell carcinoma. Oncol Rep 13: 709-714, 2005.
21. Lee JH, Kim MC, Oh SY, Kwon HC, Kim SH, Kwon KA, Lee S, Jeong JS, Choi SR and Kim HJ: Predictive value of in vitro adeno-sine triphosphate-based chemotherapy response assay in advanced gastric cancer patients who received oral 5-Fluorouracil after curative resection. Cancer Res Treat 43: 117-123, 2011.
22. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC, Delva RG, Lortholary AH, Gesta PH and Larra FG: Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 77: 441-451, 1996. (Pubitemid 26047564)
23. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Ohge H and Sueda T: Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas. J Gastrointest Surg 13: 85-92, 2009.
24. Uday CK, Devarayalu BVSK and Mahmood S: Overall survival rate in breast cancer patients treated with 5-fluorouracil: a review of randomized clinical trials. Int J Pharmaceut Biomed Res 1: 132-135, 2010.
25. Huang CL, Yokomise H, Kobayashi S, Fukushima M, Hitomi S and Wada H: Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. Int J Oncol 17: 47-54, 2000.
26. Plasencia C, Rooney PH, Taron M, Martinez-Balibrea E, McLeod HL and Abad A: Chromosomal imbalance maps of human 5FU-resistant colorectal cancer cell lines: implications in the analysis of 5FU-acquired resistance mechanisms. Int J Oncol 22: 945-953, 2003.
27. Tanaka T, Bai T and Toujima S: Establishment and characterization of monoclonal 5-fluorouracil-resistant cell lines derived from human endometrial adenocarcinoma. Int J Oncol 37: 731-736, 2010.
28. Wen J, Zheng B, Hu Y, Zhang X, Yang H, Luo KJ, Li YF and Fu JH: Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line. Oncol Rep 22: 65-71, 2009.
29. Huang M and Liu G: The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. Cancer Lett 135: 97-105, 1999.
30. Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Perry W III and Dantzig AH: The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther 4: 855-863, 2005. (Pubitemid 40767130)
31. Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T and Kohgo Y: Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 96: 457-463, 2007. (Pubitemid 46215217)
32. Fukushima M, Fujioka A, Uchida J, Nakagawa F and Takechi T: Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer 37: 1681-1687, 2001.
33. Hinoshita E, Uchiumi T, Taguchi K, Kinukawa N, Tsuneyoshi M, Maehara Y, Sugimachi K and Kuwano M: Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin Cancer Res 6: 2401-2407, 2000. (Pubitemid 30399208)
34. Kruh GD and Belinsky MG: The MRP family of drug efflux pumps. Oncogene 22: 7537-7552, 2003. (Pubitemid 37487175)
35. Matsuo N, Shiraha H, Fujikawa T, Takaoka N, Ueda N, Tanaka S, Nishina S, Nakanishi Y, Uemura M, Takaki A, Nakamura S, Kobayashi Y, Nouso K, Yagi T and Yamamoto K: Twist expression promotes migration and invasion in hepatocellular carcinoma. BMC Cancer 9: 240-251, 2009.